Immuno-Oncology Summit

From Oct 12, 2022  to Oct 14, 2022  | Location:  Boston

See the event website https://www.immuno-oncologysummit.com/ 

Do not miss our presentation on October 14th at 11:15 am during "GAMMA DELTAS, NKs AND MYELOID CELLS" session.

ICT01: A First-in-Class Clinical Stage Anti-BTN3A Antibody with the Capacity to Harness the Vg9/Vd2 T Cells in Cancer

Aude De Gassart, PhD, Director, Preclinical Research, Imcheck Therapeutics

Vg9Vd2 T cells are attractive effector cells for cancer immunotherapy due to their powerful cytolytic and pro-inflammatory properties and the positive correlation between tumor infiltration and good prognosis. ICT01, a novel anti-BTN3A mAb activating Vg9Vd2 T cells, is being evaluated in Phase I/IIa clinical studies (NCT04243499). ICT01 shows potent ability to modulate anti-tumor immune response by activating Vg9Vd2 T cells and broadening the immune response in the tumor microenvironment. Here, we will discuss the immune modulatory capacity of ICT01 and the next paths for combination approaches.

  Back to events list